Urinary Activin A is a novel biomarker reflecting renal inflammation and tubular damage in ANCA-associated vasculitis
Autoři:
Yoshinori Takei aff001; Shunsuke Takahashi aff001; Masao Nakasatomi aff001; Toru Sakairi aff001; Hidekazu Ikeuchi aff001; Yoriaki Kaneko aff001; Keiju Hiromura aff001; Yoshihisa Nojima aff002; Akito Maeshima aff001
Působiště autorů:
Department of Nephrology and Rheumatology, Gunma University Graduate School of Medicine, Maebashi, Japan
aff001; Department of Nephrology and Rheumatology, Japanese Red Cross Hospital, Maebashi, Japan
aff002
Vyšlo v časopise:
PLoS ONE 14(10)
Kategorie:
Research Article
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.pone.0223703
Souhrn
Activin A, a member of the transforming growth factor-beta superfamily, is a critical modulator of inflammation and plays a key role in controlling the cytokine cascade that drives the inflammatory response. However, the role of activin A in inflammatory kidney diseases remains unknown. To address this issue, we examined here whether activin A can be detected in the kidney and/or urine from patients with antineutrophil cytoplasmic antibody (ANCA) -associated vasculitis (AAV). Fifty-one patients who had been diagnosed with AAV and were treated in our department between November 2011 to March 2018 were included in this study. Forty-one patients had renal complications (renal AAV). Serum and urinary activin A levels were measured by enzyme-linked immunosorbent assay. Correlation of urinary activin A concentration with clinical parameters was analyzed. Urinary activin A was undetectable in healthy volunteers. In contrast, urinary activin A concentration was significantly increased in patients with renal AAV but not in those with non-renal AAV. Urinary activin A concentration decreased rapidly after immunosuppressive treatment. There was a significant correlation of urinary activin A level with urinary protein, L-FABP, and NAG. Histologic evaluation revealed that urinary activin A levels were significantly higher in patients with cellular crescentic glomeruli than in those lacking this damage. In situ hybridization demonstrated that the mRNA encoding the activin A βA subunit was undetectable in normal kidneys but accumulated in the proximal tubules and crescentic glomeruli of the kidneys of patients with renal AAV. Immunostaining showed that activin A protein also was present in the proximal tubules, crescentic glomeruli, and macrophages infiltrating into the interstitium in the kidneys of patients with renal AAV. These data suggested that urinary activin A concentration reflects renal inflammation and tubular damage in AAV and may be a useful biomarker for monitoring renal AAV.
Klíčová slova:
Enzyme-linked immunoassays – Kidneys – Macrophages – Urine – Immunohistochemistry techniques – Immunostaining – In situ hybridization – Glomeruli
Zdroje
1. Xia Y, Schneyer AL. The biology of activin: recent advances in structure, regulation and function. J Endocrinol. 2009;202(1):1–12. doi: 10.1677/JOE-08-0549 19273500; PubMed Central PMCID: PMC2704481.
2. Maeshima A, Miya M, Mishima K, Yamashita S, Kojima I, Nojima Y. Activin A: autocrine regulator of kidney development and repair. Endocr J. 2008;55(1):1–9. Epub 2007/09/11. JST.JSTAGE/endocrj/KR-113 [pii]. doi: 10.1507/endocrj.kr-113 17827789.
3. Maeshima A, Nojima Y, Kojima I. The role of the activin-follistatin system in the developmental and regeneration processes of the kidney. Cytokine Growth Factor Rev. 2001;12(4):289–98. 11544099.
4. Ritvos O, Tuuri T, Eramaa M, Sainio K, Hilden K, Saxen L, et al. Activin disrupts epithelial branching morphogenesis in developing glandular organs of the mouse. Mechanisms of development. 1995;50(2–3):229–45. doi: 10.1016/0925-4773(94)00342-k 7619733.
5. Maeshima A, Yamashita S, Maeshima K, Kojima I, Nojima Y. Activin a produced by ureteric bud is a differentiation factor for metanephric mesenchyme. J Am Soc Nephrol. 2003;14(6):1523–34. doi: 10.1097/01.asn.0000067419.86611.21 12761253.
6. Maeshima A, Vaughn DA, Choi Y, Nigam SK. Activin A is an endogenous inhibitor of ureteric bud outgrowth from the Wolffian duct. Dev Biol. 2006;295(2):473–85. doi: 10.1016/j.ydbio.2006.03.011 16643884.
7. Maeshima A, Sakurai H, Choi Y, Kitamura S, Vaughn DA, Tee JB, et al. Glial cell-derived neurotrophic factor independent ureteric bud outgrowth from the Wolffian duct. J Am Soc Nephrol. 2007;18(12):3147–55. Epub 2007/11/16. ASN.2007060642 [pii] doi: 10.1681/ASN.2007060642 18003772.
8. Maeshima A, Zhang YQ, Furukawa M, Naruse T, Kojima I. Hepatocyte growth factor induces branching tubulogenesis in MDCK cells by modulating the activin-follistatin system. Kidney Int. 2000;58(4):1511–22. doi: 10.1046/j.1523-1755.2000.00313.x 11012886.
9. Maeshima A, Shiozaki S, Tajima T, Nakazato Y, Naruse T, Kojima I. Number of glomeruli is increased in the kidney of transgenic mice expressing the truncated type II activin receptor. Biochem Biophys Res Commun. 2000;268(2):445–9. doi: 10.1006/bbrc.2000.2171 10679224.
10. Maeshima A, Zhang YQ, Nojima Y, Naruse T, Kojima I. Involvement of the activin-follistatin system in tubular regeneration after renal ischemia in rats. J Am Soc Nephrol. 2001;12(8):1685–95. 11461941.
11. Maeshima A, Maeshima K, Nojima Y, Kojima I. Involvement of Pax-2 in the action of activin A on tubular cell regeneration. J Am Soc Nephrol. 2002;13(12):2850–9. doi: 10.1097/01.asn.0000035086.93977.e9 12444203.
12. Maeshima A, Nojima Y, Kojima I. Activin A: an autocrine regulator of cell growth and differentiation in renal proximal tubular cells. Kidney Int. 2002;62(2):446–54. doi: 10.1046/j.1523-1755.2002.00463.x 12110005.
13. Yamashita S, Maeshima A, Kojima I, Nojima Y. Activin A is a potent activator of renal interstitial fibroblasts. J Am Soc Nephrol. 2004;15(1):91–101. doi: 10.1097/01.asn.0000103225.68136.e6 14694161.
14. Maeshima A, Mishima K, Yamashita S, Nakasatomi M, Miya M, Sakurai N, et al. Follistatin, an activin antagonist, ameliorates renal interstitial fibrosis in a rat model of unilateral ureteral obstruction. BioMed research international. 2014;2014:376191. Epub 2014/06/03. doi: 10.1155/2014/376191 24883308; PubMed Central PMCID: PMC4026945.
15. Gaedeke J, Boehler T, Budde K, Neumayer HH, Peters H. Glomerular activin A overexpression is linked to fibrosis in anti-Thy1 glomerulonephritis. Nephrol Dial Transplant. 2005;20(2):319–28. doi: 10.1093/ndt/gfh653 15673690.
16. Kadiombo AT, Maeshima A, Kayakabe K, Ikeuchi H, Sakairi T, Kaneko Y, et al. Involvement of infiltrating macrophage-derived activin A in the progression of renal damage in MRL-lpr mice. Am J Physiol Renal Physiol. 2017;312(2):F297–f304. Epub 2016/11/25. doi: 10.1152/ajprenal.00191.2016 27881396.
17. Takahashi S, Nakasatomi M, Takei Y, Ikeuchi H, Sakairi T, Kaneko Y, et al. Identification of Urinary Activin A as a Novel Biomarker Reflecting the Severity of Acute Kidney Injury. Sci Rep. 2018;8(1):5176. Epub 2018/03/28. doi: 10.1038/s41598-018-23564-3 29581558.
18. de Kretser DM, O'Hehir RE, Hardy CL, Hedger MP. The roles of activin A and its binding protein, follistatin, in inflammation and tissue repair. Mol Cell Endocrinol. 2012;359(1–2):101–6. doi: 10.1016/j.mce.2011.10.009 22037168.
19. Hedger MP, de Kretser DM. The activins and their binding protein, follistatin-Diagnostic and therapeutic targets in inflammatory disease and fibrosis. Cytokine Growth Factor Rev. 2013;24(3):285–95. doi: 10.1016/j.cytogfr.2013.03.003 23541927.
20. Jones KL, Mansell A, Patella S, Scott BJ, Hedger MP, de Kretser DM, et al. Activin A is a critical component of the inflammatory response, and its binding protein, follistatin, reduces mortality in endotoxemia. Proc Natl Acad Sci U S A. 2007;104(41):16239–44. doi: 10.1073/pnas.0705971104 17911255; PubMed Central PMCID: PMC2042191.
21. Ota F, Maeshima A, Yamashita S, Ikeuchi H, Kaneko Y, Kuroiwa T, et al. Activin A induces cell proliferation of fibroblast-like synoviocytes in rheumatoid arthritis. Arthritis Rheum. 2003;48(9):2442–9. doi: 10.1002/art.11249 13130463.
22. Soler Palacios B, Estrada-Capetillo L, Izquierdo E, Criado G, Nieto C, Municio C, et al. Macrophages from the synovium of active rheumatoid arthritis exhibit an activin A-dependent pro-inflammatory profile. J Pathol. 2015;235(3):515–26. doi: 10.1002/path.4466 25319955.
23. Dohi T, Ejima C, Kato R, Kawamura YI, Kawashima R, Mizutani N, et al. Therapeutic potential of follistatin for colonic inflammation in mice. Gastroenterology. 2005;128(2):411–23. doi: 10.1053/j.gastro.2004.11.063 15685552.
24. Hardy CL, King SJ, Mifsud NA, Hedger MP, Phillips DJ, Mackay F, et al. The activin A antagonist follistatin inhibits cystic fibrosis-like lung inflammation and pathology. Immunol Cell Biol. 2015. Epub 2015/03/11. doi: 10.1038/icb.2015.7 25753271.
25. Hardy CL, Nguyen HA, Mohamud R, Yao J, Oh DY, Plebanski M, et al. The activin A antagonist follistatin inhibits asthmatic airway remodelling. Thorax. 2013;68(1):9–18. doi: 10.1136/thoraxjnl-2011-201128 23051972.
26. Hubner G, Werner S. Serum growth factors and proinflammatory cytokines are potent inducers of activin expression in cultured fibroblasts and keratinocytes. Exp Cell Res. 1996;228(1):106–13. doi: 10.1006/excr.1996.0305 8892977.
27. Lieberthal JG, Cuthbertson D, Carette S, Hoffman GS, Khalidi NA, Koening CL, et al. urinary biomarkers in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. J Rheumatol. 2013;40(5):674–83. Epub 2013/04/03. doi: 10.3899/jrheum.120879 23547217; PubMed Central PMCID: PMC4505819.
28. Tam FW, Sanders JS, George A, Hammad T, Miller C, Dougan T, et al. Urinary monocyte chemoattractant protein-1 (MCP-1) is a marker of active renal vasculitis. Nephrol Dial Transplant. 2004;19(11):2761–8. Epub 2004/09/09. doi: 10.1093/ndt/gfh487 15353578.
29. Ma TT, Wang H, Wang C, Chang DY, Zhao MH, Chen M. Urinary levels of high mobility group box-1 are associated with disease activity in antineutrophil cytoplasmic autoantibody-associated vasculitis. PLoS One. 2015;10(4):e0123586. Epub 2015/04/18. doi: 10.1371/journal.pone.0123586 25884225; PubMed Central PMCID: PMC4401773.
30. Sanders JS, Huitema MG, Hanemaaijer R, van Goor H, Kallenberg CG, Stegeman CA. Urinary matrix metalloproteinases reflect renal damage in anti-neutrophil cytoplasm autoantibody-associated vasculitis. Am J Physiol Renal Physiol. 2007;293(6):F1927–34. Epub 2007/09/28. doi: 10.1152/ajprenal.00310.2007 17898039.
31. O'Reilly VP, Wong L, Kennedy C, Elliot LA, O'Meachair S, Coughlan AM, et al. Urinary Soluble CD163 in Active Renal Vasculitis. J Am Soc Nephrol. 2016;27(9):2906–16. doi: 10.1681/ASN.2015050511 26940094; PubMed Central PMCID: PMC5004645.
32. Moran SM, Monach PA, Zgaga L, Cuthbertson D, Carette S, Khalidi NA, et al. Urinary soluble CD163 and monocyte chemoattractant protein-1 in the identification of subtle renal flare in anti-neutrophil cytoplasmic antibody-associated vasculitis. Nephrol Dial Transplant. 2018. Epub 2018/11/01. doi: 10.1093/ndt/gfy300 30380100.
33. Dekkema GJ, Abdulahad WH, Bijma T, Moran SM, Ryan L, Little MA, et al. Urinary and serum soluble CD25 complements urinary soluble CD163 to detect active renal anti-neutrophil cytoplasmic autoantibody-associated vasculitis: a cohort study. Nephrol Dial Transplant. 2018. Epub 2018/03/06. doi: 10.1093/ndt/gfy018 29506265.
34. Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV. Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int. 2002;62(1):237–44. doi: 10.1046/j.1523-1755.2002.00433.x 12081583.
Článok vyšiel v časopise
PLOS One
2019 Číslo 10
- Metamizol jako analgetikum první volby: kdy, pro koho, jak a proč?
- Nejasný stín na plicích – kazuistika
- Masturbační chování žen v ČR − dotazníková studie
- Úspěšná resuscitativní thorakotomie v přednemocniční neodkladné péči
- Fixní kombinace paracetamol/kodein nabízí synergické analgetické účinky
Najčítanejšie v tomto čísle
- Correction: Low dose naltrexone: Effects on medication in rheumatoid and seropositive arthritis. A nationwide register-based controlled quasi-experimental before-after study
- Combining CDK4/6 inhibitors ribociclib and palbociclib with cytotoxic agents does not enhance cytotoxicity
- Experimentally validated simulation of coronary stents considering different dogboning ratios and asymmetric stent positioning
- Prevalence of pectus excavatum (PE), pectus carinatum (PC), tracheal hypoplasia, thoracic spine deformities and lateral heart displacement in thoracic radiographs of screw-tailed brachycephalic dogs